TEL: 044-952-0102

世界の非アルコール性脂肪性肝炎(NASH)治療薬および診断市場:パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 649745
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=108.54円で換算しております。
世界の非アルコール性脂肪性肝炎(NASH)治療薬および診断市場:パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測 Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年05月01日 ページ情報: 英文 114 Pages




第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • NASH治療薬のた有望なパイプライン
    • 世界的な糖尿病および肥満症の罹患率の上昇
    • 新たなバイオマーカー技術の登場と肝生検技術の向上
  • 阻害要因
    • 非アルコール性脂肪性肝疾患(NAFLD)に対する有効な診断法の欠如
    • 治療分野における技術進歩の停滞
  • 市場機会
  • 主な課題

第7章 非アルコール性脂肪性肝炎(NASH)市場:セグメント別

  • パイプライン治療薬別
    • 第III相試験
      • オベチコール酸(OCA)
      • アラムコル(アラキジルアミドコラン酸)
      • サログリタザル
      • エラフィブラノール
      • その他
  • 診断技術別
    • イメージング
    • 肝生検
    • バイオマーカー診断
    • その他
  • 治療法別
    • 薬物療法
    • インスリン抵抗性改善治療
    • 抗サイトカイン療法
    • 外科手術
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収分析
  • 合意・提携・協力
  • 新製品の上市

第9章 主要企業

  • AstraZeneca PLC
  • Conatus Pharmaceuticals, Inc.
  • Enzo Biochem, Inc.
  • Galmed Pharmaceuticals Ltd
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals, Inc.
  • Novo Nordisk A/S

第10章 市場の将来展望

第11章 免責事項

Product Code: 60469

Market Overview

The non-alcoholic steatohepatitis therapeutics and diagnostics market was valued at USD 7932.91 million in 2018 and is expected to reach USD 26776.58 million by 2024, with an anticipated CAGR of 25.89%, during the forecast period (2019-2024). The major factors driving the growth of the market studied are the increase in nash-affected population, the rising global prevalence of diabetic and obese populations, and increasing awareness about NAFLD/NASH. Currently, there are no FDA-approved therapies for NASH. Hence, there is a huge need to find appropriate therapeutic targets for the treatment of NASH. However, the understanding of the pathogenesis and progression of NASH has evolved and several promising novel therapies associated with the same are being evaluated. However, there is no specialized diagnostic test available in the market for NAFLD, and thus, the lack of effective diagnostic tests for non-alcoholic fatty liver disease, the slow advancements in the therapeutics field has been limiting the growth of the market.

Scope of the Report

Non-alcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is the liver inflammation and damage caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). The products used in the diagnosis and treatment are covered under this report.

Key Market Trends

Selonsertib is Expected to Experience a Lucrative Growth During the Forecast Period

Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic, and anti-fibrotic activities. The major factors driving the growth of the market are the rising prevalence of NASH across the world. The drug targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. It plays a vital role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, and certain types of cancer. In February 2019, one of the market players, Gilead Sciences, announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH), did not achieve its primary endpoint. Thus, in April 2019, it failed the Phase 3 trial, again. However, the drug was generally well tolerated, and safety results were consistent with previous studies. The company is making considerable investments in the development of drugs for NASH. Recently, in April 2019, Gilead Sciences used the AI-based platform of insitro to discover and develop treatments for NASH. Therefore, such type of activities is expected to increase the process of drug development, leading to rapid approval of the drug over the forecast period.

North America Dominates the NASH Therapeutics and Diagnostics Market

The North America market is expected to witness a CAGR of 26.12% during the forecast period. The prevalence of the nonalcoholic fatty liver disease is due to the rising trend of obesity in the region. Nonalcoholic fatty liver disease (steatohepatitis) is considered as the most common form of chronic liver disease. According to a study conducted by the Intermountain Healthcare researchers, on the economic impact of the disease, the nonalcoholic fatty liver disease affects approximately 100 million Americans every year, and the cost of the disease impacting the US healthcare system is nearly USD 32 billion, annually. Another driving factor is the rising number of obese patients in the country. For instance, as per the OECD data, 47% of the adult population in the United States may suffer from obesity by 2030, as compared to 37.7% in 2014. This represents an estimated 25% increase in obesity, by 2030. Therefore, with an increasing number of patients, the diagnostics and therapeutics are also expected to rise in the future in North America.

Competitive Landscape

Several major players, such as Galmed, Intercept, Genfit, Conatus, MediciNova, and Shire, among others, have their NASH drugs in the last stage of clinical trials. The ongoing scientific developments in the pathogenesis of NASH and the identification of novel agents targeting the disease activities are necessary for the further expansion of capacities to treat NASH and to reduce long-term clinical outcomes, such as cirrhosis, liver failure, and cancer. Investors and analysts are still somewhat skeptical about the approval chances of many of the most advanced NASH candidates. Apart from demonstrating the safety and efficacy of NASH treatments, the companies are also dealing with pricing decisions. The NASH pipeline is, therefore, worth keeping an eye on, owing to the rising prevalence of the disease, lack of available proper treatments, and the developing treatment landscape.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in NASH-affected Population
    • 4.2.2 Rising Global Prevalence of Diabetic and Obese Populations
    • 4.2.3 Increasing Awareness about NAFLD/NASH
  • 4.3 Market Restraints
    • 4.3.1 Lack of Effective Diagnostics for Non-alcoholic Fatty Liver Disease (NAFLD)
    • 4.3.2 Slow Advancements in the Therapeutic Field
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Therapeutics
      • Elafibranor
      • Ocaliva
      • Selonsertib
      • Cenicriviroc
      • Emricasan
      • Other Therapeutics
    • 5.1.2 Diagnostics
      • Imaging Techniques
      • Diagnostic Tests
      • Biopsy
  • 5.2 Geography
    • 5.2.1 North America
      • US
      • Canada
      • Mexico
    • 5.2.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.2.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.2.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Allergan PLC
    • 6.1.2 Novartis AG
    • 6.1.3 Madrigal Pharmaceuticals
    • 6.1.4 Galmed Pharmaceuticals
    • 6.1.5 Intercept Pharmaceuticals Inc.
    • 6.1.6 Gilead Sciences Inc.
    • 6.1.7 Genfit SA
    • 6.1.8 Novo Nordisk A/S
    • 6.1.9 Zydus Cadila
    • 6.1.10 Merck & Co.
    • 6.1.11 Viking Therapeutics